Navigation Links
Sangamo in Medical News

Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009

...CHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced toda...functional gains for people with diabetes." sangamo ABSTRACTS PRESENTED AT THE ADA MEETING Det... nerve function from disease-induced nerve damage. sangamo has completed a Phase 1b clinical trial (SB-509-40...

Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference

...CHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced toda...webcast live and may be accessed via a link on the sangamo BioSciences website in the Investor Relations sect...ntations. The presentation will be archived on the sangamo website for two weeks after the event. About...

Sangamo BioSciences Reports First Quarter 2009 Financial Results

...CHMOND, Calif., April 29 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) today reported... For the first quarter ended March 31, 2009, sangamo reported a consolidated net loss of $6.8 million, ...irst Quarter 2009 Highlights sangamo and its collaborators at the University of P...

MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results

...e pulmonary disease (COPD). Other Appointed H. Ward Wolff, Executive Vice President and Chief Financial Officer of sangamo BioSciences, Inc., and Scott R. Ward, Senior Vice President and President, Medtronic CardioVascular, to the board of directors. Fou...

Zinc finger proteins put personalized HIV therapy within reach

...ute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans. The Penn researchers and colleagues from sangamo Biosciences (Nasdaq:SGMO), Richmond, CA, who developed the zinc finger technology, report in an advanced online issue of Nature Biotechnology the fi...

MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors

...ere he will also serve on the audit committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer at Richmond, Calif.-based sangamo BioSciences, Inc. where he oversees the company's administrative, financial and business development activities and operations. He is also a member of...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... (Nasdaq: VICL ) Add Mitsubishi Tanabe Pharma Corporation (TSE: 4508) sangamo BioSciences Inc (Nasdaq: SGMO ) Sciele Pharma, Inc. (Nasdaq: SCRX ) C...eutics, Inc. (Nasdaq: OREX ) Repros Therapeutics Inc. (Nasdaq: RPRX ) sangamo BioSciences Inc. (Nasdaq: SGMO ) Sirtris Pharmaceuticals, Inc. (Nasdaq: ...

Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives

...roSciences CEO Discusses Future Opportunities with sangamo Technology NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced that ...be another year of significant accomplishments for sangamo as we achieve a number of major value-creating eve...

Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference

...webcast live and may be accessed via a link on the sangamo BioSciences website in the Investor Relations sect...ntations. The presentation will be archived on the sangamo website for two weeks after the event. About sangamo ...

New Gene Therapy Treats Diabetic Neuropathy

...aper demonstrate, we have had some striking success.’ The US clinical trials – carried out by Professor Tomlinson's collaborators at biotech firm sangamo BioSciences Inc – have also been encouraging with the only adverse event reported being mild injection-site reaction in four of the 12 diabetic patien...
Sangamo in Medical Technology

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...rom The Medical College of Wisconsin in Milwaukee, sangamo Biosciences, Inc., (Nasdaq: SGMO ), Sigma-Aldric... http://www.sigma-aldrich.com . About sangamo Biosciences, Inc.: sangamo BioSciences, Inc. is focused on the research and d...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

...ICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announce...ove their manufacturing capability." About sangamo sangamo BioSciences, Inc. is focused on researching and de...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

...ICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced toda...webcast live and may be accessed via a link on the sangamo BioSciences website in the Investor Relations sect...ntations. The presentation will be archived on the sangamo website for two weeks after the event. About...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced that...artners for our ZFP Therapeutic programs." sangamo Accomplishments in 2008 During the briefin...ic animal generation. Financial -- sangamo updated guidance on its expectations of 2008 year ...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

...hree to five years of diagnosis. About Sangamo sangamo BioSciences, Inc. is focused on the research and d...eering ZFPs that recognize a specific DNA sequence sangamo has created ZFP transcription factors (ZFP TF(TM))... gene expression and, consequently, cell function. sangamo is also developing sequence-specific ZFP Nucleases...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

...sylvania School of Medicine, in collaboration with sangamo scientists, was published as an Advance Online Pub... are characteristic of AIDS as well as HIV itself. sangamo expects to initiate a clinical trial to evaluate t... to infection by R5 HIV strains. About Sangamo sangamo BioSciences, Inc. is focused on the research and d...

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

... SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today...erve damage. About the SB-509 Clinical Program sangamo has three ongoing Phase 2 studies in diabetics wit...the legs and feet. As announced on June 6, 2008, sangamo will expand the Phase 2 study by enrolling approxi...

Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs

... sangamo Announces Completion of Accrual and Expansion Plan... SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today... nerve function from disease-induced nerve damage. sangamo is currently evaluating SB-509 in three ongoing Ph...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

...el SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced...tegy is effective in animal models of the disease. sangamo expects to file an Investigative New Drug (IND) ap...t from these advances." Data Presented at AACR sangamo scientists have engineered ZFNs specifically targe...

Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines

... -- Sigma-Aldrich Corporation (Nasdaq: SIAL ) and sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today...r production of recombinant proteins. In addition, sangamo is using this technology to develop ZFP Therapeuti...ologies." The work, co-authored by scientists at sangamo and Pfizer Inc, was published online on March 21, ...
Sangamo in Biological News

Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference

... RICHMOND, Calif., May 7 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today...webcast live and may be accessed via a link on the sangamo BioSciences website in the Investor Relations sect...ntations. The presentation will be archived on the sangamo website for two weeks after the event. About San...

Trial success for diabetic nerve therapy

...e paper demonstrate, we have had some striking success." The US clinical trials ?carried out by Professor Tomlinson's collaborators at biotech firm sangamo BioSciences Inc ?have also been encouraging with the only adverse event reported being mild injection-site reaction in four of the 12 diabetic patient...

Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection

... sangamo BioSciences, Inc. today announced that data from i...e. In its anti-HIV preclinical research program, sangamo has designed ZFNs that can be used to disrupt the ..., HIV was once again able to infect these cells. sangamo has shown disruption of the CCR5 gene in a number ...

Diabetic nerve therapy shows 'striking' results

... University of Manchester, working with colleagues at American biotech firm sangamo BioSciences Inc, have discovered a way of stimulating genes that prevent ne...lved in the clinical trials. Dr Mark Kipnes, a clinical investigator for sangamo and endocrinologist at the clinic, said: "Currently, there are no effective...

Researchers pioneer new gene therapy technique using natural repair process

...ng a DNA repair process known as homologous recombination, Dr. Matthew Porteus of UT Southwestern, working with scientists from Richmond, Calif.-based sangamo Biosciences, was able to replace a mutated version of the gene that encodes a portion of the interleukin-2 receptor (IL-2R) in human cells, restoring ...
Sangamo in Biological Technology

Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement

Milestone Achieved A Year Ahead of Schedule ST. LOUIS and RICHMOND, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced it has reached a major production capacity milestone as part of its agreement with Sigma-Aldrich Corporation (Nasdaq: SI...

Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants

Dow AgroSciences Will Sublicense Sangamo's Technology in Plant Agriculture Under the Trademark EXZACT(TM) Precision Traits SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW ), announced today at the 20...

Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration

ZFP Technology Accelerates Precision Gene Control, Trait Stacking in Commercial Crop Species INDIANAPOLIS and RICHMOND, Calif., June 5 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the successful completio...

Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration

CEO of Dow AgroSciences Announces Milestone in Wall Street Presentation INDIANAPOLIS, and RICHMOND, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced the successful completion of a key research milestone as part of the...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

...ICHMOND, Calif., July 29 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) today reported... For the second quarter ended June 30, 2009, sangamo reported a consolidated net loss of $4.5 million, ...ositive Phase 2 ZFP Therapeutic data at ADA 2009. sangamo announced the presentation of previously unrelease...

OMT announces a breakthrough in the development of a novel human antibody platform

...uly 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL),... In the study, OMT scientists and its collaborators used ZFNs developed by sangamo BioSciences, Inc. to knockout a gene encoding rat immunoglobulin. The mutat...

Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast

...ICHMOND, Calif., July 22 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announce...ants may access the live webcast via a link on the sangamo BioSciences website in the Investors section under... number for the replay is 9591497. About sangamo ...

Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference

...RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced toda...webcast live and may be accessed via a link on the sangamo BioSciences website in the Investor Relations sect...ntations. The presentation will be archived on the sangamo website for two weeks after the event. About...

Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research

...ICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- sangamo BioSciences, Inc. (Nasdaq: SGMO ), the world lea...vative global health research project conducted by sangamo scientists and titled "Zinc Finger Nucleases for ...V entry, are naturally resistant to HIV infection. sangamo has designed and engineered zinc finger DNA-bindin...

Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize

...etween Dow AgroSciences and Richmond, Calif. based sangamo BioSciences Inc. was initiated in October 2005. Th...ent of products in plants and plant cell cultures. sangamo BioSciences and Dow AgroSciences worked together o...Dow AgroSciences LLC ZFN™ is a trademark of sangamo Biosciences Inc. ### Read the full story at ...
Other Tags
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
(Date:4/22/2014)... way of asking him or her to behave better. ... of the immune system tend to misbehave with age, ... cells are known to misbehave similarly during spaceflight, researchers ... to better understand how our immune systems change as ... Aging, part of the National Institutes of Health, have ...
(Date:4/22/2014)... MA, April 22, 2014 Researchers from NeuroPhage ... with the potential to treat most neurodegenerative diseases ... Alzheimer,s, Parkinson,s and Huntington,s diseases. These molecules are ... amyloid interaction motif, or GAIM, which recognizes a ... just one type of misfolded protein. This approach ...
(Date:4/21/2014)... brain research that can one day be applied to ... Khanh (Kate) Nguyen has been recognized as one of ... mathematics and physics, Nguyen is among the 2014 recipients ... of the most prestigious awards available to undergraduate students, ... students majoring in mathematics, the natural sciences or engineering ...
Breaking Biology News(10 mins):For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 2NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 3UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4
Other Contents